医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Cardiac Dimensions Announces Initial Enrollments in REDUCE FMR Clinical Trial

2015年06月25日 PM05:00
このエントリーをはてなブックマークに追加


 

KIRKLAND, Wash.

Cardiac Dimensions® today announced that the first patients have been enrolled in the REDUCE FMR clinical trial. REDUCE FMR is a prospective, double-blind, randomized multi-center trial, evaluating the company’s minimally-invasive CARILLON® Mitral Contour System®.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150625005230/en/

The CARILLON® Mitral Contour System® (Photo: Business Wire)

The CARILLON® Mitral Contour System® (Photo: Business Wire)

Involving up to 20 leading hospitals in Europe and Australia, REDUCE FMR will randomize 120 patients and is designed to establish CARILLON as the gold standard treatment for Functional Mitral Regurgitation (FMR) – a condition in which blood flow to the body is reduced due to an abnormally enlarged mitral valve. All patients enrolled in the study are on an optimized heart failure medication regimen and are then randomized into two groups: one additionally treated with the CARILLON device and the second remaining on an optimized regimen of heart failure medications, the present gold standard.

The study design contains some unique elements aimed at optimizing recruitment and enrollment, including a 3:1 randomization ratio allowing for more data to be collected with the CARILLON device and a cross-over registry which allows control patients to receive CARILLON treatment at the end of their 12-month follow up. A built-in exercise echocardiographic sub-study will further evaluate the CARILLON device’s ability to reduce mitral regurgitation, improve functional capacity and quality of life as well as induce reverse ventricular remodeling in a symptomatic heart failure patient population both at rest and during exercise.

The REDUCE FMR clinical trial follows three successful multi-center studies, featuring the CARILLON device – the AMADEUS, TITAN and TITAN II trials. “My experiences with CARILLON have been extremely positive. As an investigator in the last two multi-center trials involving the CARILLON therapy I’ve seen significant clinical improvement in patients who receive the device,” said Janusz Lipiecki, M.D., of Clinique Pôle Santé République in Clermont Ferrand, France. “In this latest landmark trial, we expect to firmly establish the magnitude of benefit that patients receive from CARILLON.”

“The outcomes from REDUCE FMR will be added to the positive data already collected from nearly 100 treated patients evaluated during the three previous prospective trials,” said Rick Stewart, Chief Executive Officer of Cardiac Dimensions. “This is the first randomized, blinded study in the field of FMR, making its results of critical importance in understanding the clinical significance of the CARILLON device in this underserved patient population.”

About CARILLON® Mitral Contour System®

The CARILLON Mitral Contour System is a percutaneous mitral annuloplasty treatment option that can be deployed rapidly and safely1, utilizing standard interventional techniques. The implantable device consists of a distal anchor and a proximal anchor connected by a shaping ribbon and utilizes the heart’s venous anatomy to reshape the mitral annulus. This approach allows for reduction of the dilated annulus, addressing a root cause of functional mitral regurgitation (FMR). CARILLON has demonstrated compelling efficacy, significantly improving patients’ symptoms, mitral regurgitation and quality of life. In addition, all adjunctive treatment options remain available after using CARILLON, making it an ideal first-line therapy for FMR.

About Functional Mitral Regurgitation

An estimated 70 percent of the 26 million people worldwide with heart failure suffer from functional mitral regurgitation (FMR). FMR typically results from the dilation of the left ventricle, which is the main pumping chamber in the heart. As the left ventricle increases in size, the mitral valve also expands. This dimensional increase leads to mitral regurgitation, which significantly reduces the amount of blood flow out of the left ventricle and on to the body and its organs. FMR has been associated with high rates of mortality, reduced functional capacity, poor quality of life and an increase in patient hospitalizations. Current mainstream therapies to address FMR are limited. A majority of patients become refractory to medical therapy, which is the current standard of care and traditional surgical intervention is associated with high rates of operative morbidity and mortality.

About Cardiac Dimensions®

Cardiac Dimensions is a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company’s initial technology platform, the CARILLON Mitral Contour System has been designed to address functional mitral regurgitation, utilizing a novel percutaneous approach. Cardiac Dimensions has operations in Kirkland, Washington; Sydney, Australia and Offenbach, Germany. For more information, visit the company’s web site: http://www.cardiacdimensions.com.

Cardiac Dimensions, CARILLON and Mitral Contour System are registered trademarks of Cardiac Dimensions.

1 Siminiak T, Wu JC, Haude M, Hoppe UC, Sadowski J, Lipiecki J, Fajadet J, Shah AM, Feldman T, Kaye DM, Goldberg S, Mehta N, Solomon SD, Levy WC, Reuter DG. Treatment of functional mitral regurgitation by percutaneous annuloplasty: Results of the TITAN Trial. Eur J Heart Fail. 2012;14:931-38.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150625005230/en/

CONTACT

Cardiac Dimensions®
Omari Bouknight
Vice
President Sales and Marketing
63067 Offenbach
Phone: (425)
505-1455
obouknight@cardiacdimensions.com
or
Media
Contacts

USA & Australia: Helen Winkler
Phone:
001.949.606.2008
helen@bentoncommunications.com
or
Europe:
Baerbel Mattka
Phone: 0049.69.56005366
bm@wortwechsel-gesundheit.de

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表
  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402
  • Bertin与Zymo Research宣布达成新的合作